Are health technology assessments of pharmacogenetic tests feasible?: A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen

N. Fleeman; K. Payne; W.G. Newman; S.J. Howell; A. Boland; J. Oyee; C.M. Saborido; A.F. Santander; R. Dickson

doi:10.2217/pme.13.60

Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen

N. Fleeman, K. Payne, W.G. Newman, S.J. Howell, A. Boland, J. Oyee, C.M. Saborido, A.F. Santander, R. Dickson

Research output: Contribution to journal › Article › peer-review

Original language	Undefined
Journal	Personalized Medicine
Volume	10
Issue number	6
DOIs	https://doi.org/10.2217/pme.13.60
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/pme.13.60

Cite this

@article{70b50a2f287e48efadbca88ac208195a,

title = "Are health technology assessments of pharmacogenetic tests feasible?: A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen",

author = "N. Fleeman and K. Payne and W.G. Newman and S.J. Howell and A. Boland and J. Oyee and C.M. Saborido and A.F. Santander and R. Dickson",

year = "2013",

doi = "10.2217/pme.13.60",

language = "Undefined",

volume = "10",

journal = "Personalized Medicine",

issn = "1741-0541",

publisher = "Taylor & Francis",

number = "6",

}

TY - JOUR

T1 - Are health technology assessments of pharmacogenetic tests feasible?

T2 - A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen

AU - Fleeman, N.

AU - Payne, K.

AU - Newman, W.G.

AU - Howell, S.J.

AU - Boland, A.

AU - Oyee, J.

AU - Saborido, C.M.

AU - Santander, A.F.

AU - Dickson, R.

PY - 2013

Y1 - 2013

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84881397547&partnerID=MN8TOARS

U2 - 10.2217/pme.13.60

DO - 10.2217/pme.13.60

M3 - Article

SN - 1741-0541

VL - 10

JO - Personalized Medicine

JF - Personalized Medicine

IS - 6

ER -

Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen

UN SDGs

Access to Document

Other files and links

Cite this